Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 19Recruiting 11Active not recruiting 5Unknown 4Not yet recruiting 3Withdrawn 2Terminated 2Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 131Neoplasms, Plasma Cell 21Recurrence 20Lymphoma 14Lymphoma, Non-Hodgkin 13Leukemia, Lymphocytic, Chronic, B-Cell 13Leukemia, Myeloid, Acute 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myeloproliferative Disorders 11Lymphoma, Mantle-Cell 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 11Leukemia 11Neoplasms 10Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Large B-Cell, Diffuse 10Hodgkin Disease 10Primary Myelofibrosis 9Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 9Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 9Congenital Abnormalities 9Waldenstrom Macroglobulinemia 8Sezary Syndrome 8Pdgfra-Associated Chronic Eosinophilic Leukemia 8Mycosis Fungoides 8Lymphoma, T-Cell, Cutaneous 8Leukemia, Neutrophilic, Chronic 8Leukemia, Myeloid, Accelerated Phase 8

Interventions

Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Paraproteinemias × Plasma cell × Clear all
NCT03591614 2023-08-18

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Withdrawn
Plasma cell

Smoldering Multiple Myeloma, Paraproteinemias, Neoplasms, Plasma Cell

NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Celgene

Phase 3 Withdrawn
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡